Results of a phase III study examing ofatumumab compared with rituximab for treatment of relapsed indolent lymphomas.
Home / Resource Library / A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy